A clinical study of ADVM-022 at the 2 x 10^11 vg/eye and a lower dose in patients with wet AMD
Latest Information Update: 29 Sep 2021
At a glance
- Drugs Ixoberogene soroparvovec (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Adverum Biotechnologies
- 29 Sep 2021 New trial record